ORAMED PHARMACEUTICALS INC.
ORMP · Pharmaceutical Preparations · 40.9M shares · +13%/yr ↑ dilution · EDGAR filings ↗
Net buyback after stock comp: -$2M (gross $2M, SBC $4M)
Grade
C57Cash-rich biopharma shell after a failed Phase 3, now living off investment gains rather than an operating business.
Strengths
- Very strong liquidity and runway (current 6.98, cash runway ~26 quarters, 93rd pct) with a sizeable investment portfolio
- Headline net income, ROA (97th pct) and ROE (84th pct) are positive — though driven by financial/investment gains
Risks
- Lead Phase 3 oral insulin trial (ORA-D-013-1) missed primary and secondary endpoints; core technology divested to OraTech/Lifeward
- Operating margin deeply negative (-754%) and gross margin ~0.7% (4th pct); value now hinges on illiquid stakes (Scilex, Lifeward, Alpha Tau)
Notable findings
- Exec changeRecent 8-K item 5.02 8-K ↗
- Cash burnNegative free cash flow (-9.2M)
- Chronic dilutionShare count +13%/yr over 3y (dilution, book value/share -8%)
- Notable holderHeld by 3 notable fund(s): RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, FMR LLC (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Gross margin
0.7%
Operating margin
-754.4%
Net margin
3202.5%
Return on equity
32.1%
Return on assets
27.7%
Current ratio
7.0×
Free cash flow
-$9M
Tangible book value
$200M
Cash & investments
$60M
Cash runway
26q
Stock comp / revenue
299.6%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-30 | KIDRON NADAV | Tax withheld | 45K | $3.31 |
| 2026-03-30 | Kidron Miriam | Tax withheld | 435K | $3.31 |
| 2026-03-17 | Kidron Miriam | Grant | 120K | — |
| 2026-03-17 | KIDRON NADAV | Grant | 167K | — |
| 2026-03-17 | Hexter Joshua | Grant | 96K | — |
| 2026-03-17 | Gabay Avraham | Grant | 96K | — |
| 2026-03-12 | KIDRON NADAV | Gift | 100K | — |
| 2026-01-22 | KIDRON NADAV | Option exercise | 109K | — |
| 2026-01-22 | Kidron Miriam | Option exercise | 19K | — |
| 2026-01-22 | Hexter Joshua | Option exercise | 19K | — |
| 2026-01-22 | Gabay Avraham | Option exercise | 19K | — |
| 2026-01-14 | Kidron Miriam | Gift | 86K | — |
| 2025-12-31 | Reznick Yehuda | Grant | 30K | — |
| 2025-12-31 | Reznick Yehuda | Grant | 6.2K | — |
| 2025-12-31 | KIDRON NADAV | Grant | 233K | — |
| 2025-12-31 | KIDRON NADAV | Grant | 327K | — |
| 2025-12-31 | Kidron Miriam | Grant | 121K | — |
| 2025-12-31 | Kidron Miriam | Grant | 115K | — |
| 2025-12-31 | Hexter Joshua | Grant | 97K | — |
| 2025-12-31 | Hexter Joshua | Grant | 115K | — |
| 2025-12-31 | Shapiro Benjamin | Grant | 30K | — |
| 2025-12-31 | Shapiro Benjamin | Grant | 3.5K | — |
| 2025-12-31 | Mayer Arie | Grant | 30K | — |
| 2025-12-31 | Mayer Arie | Grant | 4.9K | — |
| 2025-12-31 | Aghion Daniel | Grant | 30K | — |
| 2025-12-31 | Aghion Daniel | Grant | 6.2K | — |
| 2025-12-31 | Gabay Avraham | Grant | 81K | — |
| 2025-12-31 | Gabay Avraham | Grant | 115K | — |
| 2025-06-05 | Mayer Arie | Grant | 30K | — |
| 2025-06-05 | Mayer Arie | Grant | 7.0K | — |
| 2025-06-05 | Aghion Daniel | Grant | 30K | — |
| 2025-06-05 | Aghion Daniel | Grant | 8.4K | — |
| 2025-06-05 | Reznick Yehuda | Grant | 30K | — |
| 2025-06-05 | Reznick Yehuda | Grant | 8.4K | — |
| 2025-06-05 | Sank Leonard | Grant | 30K | — |
| 2025-06-05 | Sank Leonard | Grant | 6.5K | — |
| 2025-06-05 | Shapiro Benjamin | Grant | 30K | — |
| 2025-06-05 | Shapiro Benjamin | Grant | 4.7K | — |
| 2025-02-11 | Kidron Miriam | Grant | 74K | — |
| 2025-02-11 | Kidron Miriam | Grant | 52K | — |
| 2025-02-11 | Kidron Miriam | Grant | 67K | — |
| 2025-02-11 | Hexter Joshua | Grant | 45K | — |
| 2025-02-11 | Hexter Joshua | Grant | 48K | — |
| 2025-02-11 | Hexter Joshua | Grant | 33K | — |
| 2025-02-11 | KIDRON NADAV | Grant | 141K | — |
| 2025-02-11 | KIDRON NADAV | Grant | 186K | — |
| 2025-02-11 | KIDRON NADAV | Grant | 100K | — |
| 2025-02-11 | Gabay Avraham | Grant | 34K | — |
| 2025-02-11 | Gabay Avraham | Grant | 42K | — |
| 2025-01-02 | Kidron Miriam | Grant | 207K | — |
| 2025-01-02 | KIDRON NADAV | Grant | 434K | — |
| 2025-01-02 | Gabay Avraham | Grant | 188K | — |
| 2025-01-02 | Hexter Joshua | Grant | 194K | — |
All non-derivative Form 4 activity (SEC), newest first.
Supply chain
Customers (2)
- Medicox
- OraTech
Suppliers (1)
- Integrium LLC
Named in the 10-K; linked when we track them.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-03-31 | Material agreementAcquisition/disposition | filing ↗ |
| 2026-02-20 | Material agreementExhibits | filing ↗ |
| 2026-01-14 | Material agreementOtherExhibits | filing ↗ |
| 2026-01-07 | OtherExhibits | filing ↗ |
| 2025-12-31 | Exec/director change | filing ↗ |
| 2025-12-31 | Other | filing ↗ |
| 2025-11-17 | Material agreement3.03Exhibits | filing ↗ |
| 2025-11-17 | ResultsExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 10-Q | 2026-05-19 | 2026-03-31 | 0001213900-26-059112 ↗ |
| 8-K | 2026-03-31 | 2026-03-25 | 0001213900-26-037474 ↗ |
| 10-K | 2026-03-26 | 2025-12-31 | 0001213900-26-034835 ↗ |
| 8-K | 2026-02-20 | 2026-02-19 | 0001012975-26-000195 ↗ |
| 8-K | 2026-01-14 | 2026-01-12 | 0001213900-26-004382 ↗ |
| 8-K | 2026-01-07 | 2026-01-07 | 0001213900-26-001983 ↗ |
| 8-K | 2025-12-31 | 2025-12-31 | 0001213900-25-127133 ↗ |
| 8-K | 2025-12-31 | 2025-12-30 | 0001012975-25-000992 ↗ |
| 8-K | 2025-11-17 | 2025-11-16 | 0001213900-25-111298 ↗ |
| 8-K | 2025-11-17 | 2025-11-17 | 0001213900-25-111310 ↗ |
| 10-Q | 2025-11-13 | 2025-09-30 | 0001213900-25-109980 ↗ |
| 8-K | 2025-10-24 | 2025-10-20 | 0001213900-25-101825 ↗ |